CSB 2.25 CSB 2.25 Addition of remifentanil to schedule II; transfer of dronabinol from schedule II to schedule III; addition of fenproporex, modafinil, sibutramine, zaleplon and zolpidem to schedule IV; spelling correction of carfentanil.
CSB 2.25(1)(1)Section 961.16 (3) (cm), Stats., is amended to read:
(cm) Carfentanil;
CSB 2.25(2) (2)Section 961.16 (3) (xm), Stats., is created to read:
(xm) Remifentanil;
CSB 2.25(3) (3)Section 961.16 (10) (a), Stats., is repealed.
CSB 2.25(4) (4)Section 961.18 (4m), Stats., is created to read:
(4m) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. food and drug administration approved drug product. (Other names for dronabinol are (6aR-trans)-6a, 7, 8, 10a-tetrahydro-6, 6. 9-trimethyl-3-pentyl-6H-dibenzo(b, d)pyran-1-ol, and (-)-delta-9-(trans)-tetrahydrocannabinol.)
CSB 2.25(5) (5)Section 961.20 (2) (o) and (p), Stats., is created to read:
(o) Zaleplon.
(p) Zolpidem.
CSB 2.25(6) (6)Section 961.20 (2m) (at), (bu) and (f), Stats., is created to read:
(at) Fenproporex.
(bu) Modafinil.
(f) Sibutramine.
CSB 2.25 History History: Cr. Register, July, 2000, No. 535, eff. 8-1-00.
CSB 2.26 CSB 2.26 Addition of dihydroetorphine to schedule II.
CSB 2.26(1)(1)Section 961.16 (2) (a) 4r., Stats., is created to read:
4r. Dihydroetorphine.
CSB 2.26 History History: CR 01-071: Cr. Register November 2001 No. 551, eff. 12-1-01.
CSB 2.28 CSB 2.28 Addition of dichloralphenazone to schedule IV.
CSB 2.28(1)(1)Section 961.20 (2) (cs), Stats., is created to read:
Section 961.20 (2) (cs) Dichloralphenazone;
CSB 2.28 History History: CR 02-025: Cr. Register October 2002 No. 562, eff. 11-1-02.
CSB 2.29 CSB 2.29 Transfer of buprenorphine from schedule V to schedule III.
CSB 2.29(1) (1)Section 961.18 (5m), Stats., is created to read:
Section 961.18 (5m) Narcotic Drugs Not Limited by Quantity. Any material, compound, mixture, or preparation containing any of the following narcotic drugs, including any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation:
(a) Buprenorphine
CSB 2.29 History History: CR 03-056: cr. Register January 2004 No. 577, eff. 2-1-04.
CSB 2.30 CSB 2.30 Addition of gamma-hydroxybutyric acid to schedule III.
CSB 2.30(1) (1)Section 961.18 (3) (o), Stats., is created to read:
Section 961.18 (3) (o) Any drug product containing gamma-hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the federal food, drug and cosmetic act:
1. Gamma-hydroxybutyric acid.
CSB 2.30 History History: CR 03-057: cr. Register January 2004 No. 577, eff. 2-1-04.
CSB 2.31 CSB 2.31 Addition of 2,5 dimethoxy-4-(n)- propylthiophenethylamine (2C-T-7) to schedule I.
CSB 2.31(1)(1)Section 961.14 (4) (wh), Stats., is created to read:
Section 961.14 (4) (wh) 2,5 dimethoxy-4-(n)- propylthiophenethylamine, commonly known as “2C-T-7";
CSB 2.31 History History: CR 06-058: cr. Register April 2007 No. 616, eff. 5-1-07.
CSB 2.32 CSB 2.32 Addition of N- benzylpiperazine (BZP) to schedule I.
CSB 2.32(1)(1)Section 961.14 (7) (q), Stats., is created to read:
Section 961.14 (7) (q) N - benzylpiperazine, commonly known as “BZP."
CSB 2.32 History History: CR 06-058: cr. Register April 2007 No. 616, eff. 5-1-07.
CSB 2.33 CSB 2.33 Addition of alpha-methyltryptamine (AMT) to schedule I.
CSB 2.33(1)(1)Section 961.14 (4) (wi), Stats., is created to read:
Section 961.14 (4) (wi) Alpha-methyltryptamine, commonly known as “AMT";
CSB 2.33 History History: CR 06-059: cr. Register April 2007 No. 616, eff. 5-1-07.
CSB 2.34 CSB 2.34 Addition of 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT).
CSB 2.34(1)(1)Section 961.14 (4) (wj), Stats., is created to read:
Section 961.14 (4) (wj) 5-methoxy-N, N-diisopropyltryptamine, commonly known as “5-MeO-DIPT";
CSB 2.34 History History: CR 06-059: cr. Register April 2007 No. 616, eff. 5-1-07.
CSB 2.35 CSB 2.35 Addition of lisdexamfetamine to schedule II.
CSB 2.35(1)(1)Section 961.16 (5) (e), Stats., is created to read:
Section 961.16 (5) (e) Lisdexamfetamine, commonly known as “Vyvanse TM."
CSB 2.35 History History: CR 10-112: cr. Register April 2011 No. 664, eff. 5-1-11.
CSB 2.36 CSB 2.36 Addition of tramadol to schedule IV. Section 961.20 (4) (e), Stats., is created to read:
Section 961.20 (4) (e) Tramadol, including any of its isomers and salts of isomers.
CSB 2.36 History History: cr. Affirmative action order under s. 968.11 (4), Stats., Register August 2014 No. 704, eff. 9-1-14; CR 15-008: cr. Register October 2015 No. 718, eff. 11-1-15.
CSB 2.37 CSB 2.37 Rescheduling of hydrocodone combination products. Sections 961.18 (5) (c) and (d), Stats., are repealed.
CSB 2.37 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2014 No. 706, eff. 11-1-14; CR 15-007: cr. Register October 2015 No. 718, eff. 11-1-15.
CSB 2.38 CSB 2.38 Addition of suvorexant to schedule IV. Section 961.20 (2) (mr), Stats., is created to read:
Section 961.20 (2) (mr) Suvorexant.
CSB 2.38 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2014 No. 706, eff. 11-1-14; CR 15-009: cr. Register October 2015 No. 718, eff. 11-1-15.
CSB 2.39 CSB 2.39 Exclusion of naloxegol. Section 961.16 (2) (a) (intro.), Stats., is amended to read:
961.16 (2) (a) (intro) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, nalmefene, naloxegol, naloxone and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.39 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register April 2015 No. 711B, eff. 4-1-15; CR 15-068: cr. Register August 2016 No. 728, eff. 9-1-16.
CSB 2.40 CSB 2.40 Exclusion of [123I]ioflupane. Section 961.16 (2) (b), Stats., is amended to read:
(b) Coca leaves and any salt, compound, derivative or preparation of coca leaves. Decocainized coca leaves or extractions which do not contain cocaine or ecgonine are excluded from this paragraph. [123I]Ioflupane is excluded from this paragraph. The following substances and any of their salts, esters, isomers and salts of esters and isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.40 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2015 No. 718A3, eff. 10-19-15; correction made under s. 35.17, Stats., Register October 2015 No. 718; CR 16-060: cr. Register May 2017 No. 737, eff. 6-1-17.
CSB 2.41 CSB 2.41 Scheduling of beta-hydroxythiofentanyl and butyryl fentanyl. Sections 961.14 (2) (eu) and (ey) are created to read:
961.14 (2) (eu) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide)
(ey) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide)
CSB 2.41 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2016 No. 728, eff. 7-18-16; CR 16-081: cr. Register July 2017 No. 739, eff. 8-1-17.
CSB 2.42 CSB 2.42 Scheduling of furanyl fentanyl. Section 961.14 (2) (ne) is created to read:
961.14 (2) (ne) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide).
CSB 2.42 History History: EmR1626: emerg. cr., eff. 9-1-16; CR 16-059: cr. Register May 2017 No. 737, eff. 6-1-17.
CSB 2.43 CSB 2.43 Addition of brivaracetam to schedule V. Section 961.22 (6), Stats., is created to read:
961.22 (6) BRIVARACETAM. Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide), including its salts, isomers or salts of isomers.
CSB 2.43 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register September 2016 No. 729, eff. 9-26-16; CR 17-009: cr. Register July 2017 No. 739, eff. 8-1-17.
CSB 2.44 CSB 2.44 Addition of thiafentanil to schedule II. Section 961.16 (3) (zx), Stats., is created to read:
961.16 (3) (zx) Thiafentanil.
CSB 2.44 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2016 No. 730, eff. 10-3-16; CR 17-007: cr. Register July 2017 No. 739, eff. 8-1-17.
CSB 2.45 CSB 2.45 Addition of AB-FUBINACA and ADB-PINACA to schedule I. Section 961.14 (4) (tb) 32. and 33., Stats., is created to read:
961.14 (4) (tb) 32. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as AB-FUBINACA.
33. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, commonly known as ADB-PINACA.
CSB 2.45 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2016 No. 730, eff. 10-10-16; CR 17-008: cr. Register July 2017 No. 739, eff. 8-1-17.
CSB 2.46 CSB 2.46 Addition of acetyl fentanyl to schedule I. Section 961.14 (2) (ae), Stats., is created to read:
961.14 (2) (ae) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide).
CSB 2.46 History History: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2016 No. 731, eff. 11-21-16; CR 17-021: cr. Register November 2017 No. 743, eff. 12-1-17.
CSB 2.47 CSB 2.47 Addition of AH-7921 to schedule I. Section 961.14 (2) (aj), Stats., is created to read:
961.14 (2) (aj) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide).
Loading...
Loading...
Published under s. 35.93, Stats. Updated on the first day of each month. Entire code is always current. The Register date on each page is the date the chapter was last published.